Despite this, 35-40% of patients with CML on TKIs develop resistance (16), often due to the clonal outgrowth of CML cells harbouring BCR-ABL point mutations (recently reviewed in (17). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.